Overview of the RFI
The Biomedical Advanced Research and Development Authority (BARDA) is looking at a specific problem: how to repurpose specialized equipment originally designed to manufacture an emergency autoinjector platform into a broader drug delivery solution. Through the Rapid Response Partnership Vehicle (RRPV), BARDA released a new Request for Information (RFI), “Repurposing Equipment for Drug Delivery” (REDD), to understand what capabilities exist for taking possession of this equipment and converting it into a novel delivery platform.
The focus is on chemical medical countermeasures, but BARDA also notes that commercially relevant applications may exist across multiple CBRN indications. In practice, this is not just about one device or one use-case. It is about identifying whether existing technical and manufacturing capabilities can be redirected toward a flexible delivery platform with broader utility.
What BARDA is Looking For
The equipment described in the RFI was originally customized for a collapsible, glass-free primary drug cartridge made from high-barrier films. BARDA is seeking input on whether respondents can assume ownership of that equipment and repurpose it for a novel drug delivery device such as an autoinjector or another single-use delivery system. The agency specifically calls out interest in novel autoinjector platforms and needleless drug delivery devices.
The RFI asks respondents to describe several areas in detail:
- Organizational overview and prior experience with drug delivery devices and manufacturing
- Proposed solution and how it differs from current products
- Infrastructure, facilities, and readiness
- Collaborations, awards, and relevant publications
- Development program structure, milestones, tests, timelines, and resource needs
BARDA also asks respondents to assess the maturity of their solution, discuss platform workflow and process, identify limitations and potential workarounds, and address the intellectual property landscape.
Submission Requirements and Dates
Responses are due July 23, 2026 by 1:00 p.m. ET and must be submitted via the designated RFI submission form.
Respondents are instructed to clearly mark proprietary information, avoid submitting classified material, and note that non-federal advisors under NDA may have access to submissions. The RFI is explicitly for information-gathering only and does not constitute an RPP or a commitment to make awards.
Respondents do not need to be members of the RRPV consortium to submit to this RFI, but membership would be required for any future RPP associated with this topic.
What Innovators Should Takeaway
For teams working on drug delivery devices, autoinjector platforms, or related manufacturing and considering a submission, a strong response should:
- Show actual technical maturity, not just an idea
- Be clear about where your platform is ready and where you need partners to deliver an end-to-end solution
- Lay out a practical development path with clear milestones, timelines, and decision points
The goal is to show how your technology could turn a very specific set of assets into a viable, scalable delivery platform.
If your company is considering applying for federal funding, your journey starts here. EverGlade is a national advisory firm helping innovators navigate the federal funding ecosystem. We support companies across the funding lifecycle, from early-stage strategy through proposal development, negotiations, and post-award execution, connecting breakthrough innovation with non-dilutive funding.
For additional information, schedule a free consultation with our team.
